BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16

• 

  Huntington’s disease

  Roche scraps 2 Huntington’s studies, handing Ionis more bad news

  Roche’s decision to discontinue the Ionis-partnered trials came soon after the biotech sustained a late-stage failure in ATTR-CM.

  July 10, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space

  The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics.

  July 10, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• Press Releases

  BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission

  July 10, 2026

   · 

  5 min read
• Press Releases

  Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 10, 2026

  July 10, 2026

   · 

  1 min read
• Press Releases

  NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression

  July 10, 2026

   · 

  6 min read
• Press Releases

  VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

  July 10, 2026

   · 

  10 min read
• Press Releases

  Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  July 10, 2026

   · 

  4 min read
• Press Releases

  SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

  July 10, 2026

   · 

  5 min read
• 

  Antibody-drug conjugates

  GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China

  GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.

  July 10, 2026

   · 

  1 min read

   · 

  Gabrielle Masson
• 

  Alzheimer’s disease

  AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

  The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.

  July 10, 2026

   · 

  6 min read

   · 

  Michael Gibney